ReviewInfection2014
The current spectrum of infection in cancer patients with chemotherapy related neutropenia.
Review in Infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.Pharmaceutical biology · 2024Pooled it
- Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.The Cochrane database of systematic reviews · 2017Pooled it
- Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review.Infection · 2015Pooled it
- Association between oral ulcerative lesions, oral infections, and fever during the pre-engraftment phase after hematopoietic cell transplantation: results from the Orastem study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Beyond Oral Health: Personalized Strategies for Managing Oral Infections in Neutropenic Patients.Journal of personalized medicine · 2026Review
- Influence of chemotherapy intensity on opportunistic fungal infection risk in non-small cell lung carcinoma: a retrospective study.Frontiers in medicine · 2026Article
- Synthesis, Crystal Structure, Antitumor, and Antimicrobial Activity of Novel Copper(II) Complexes with a Coumarin Derivative Containing a Histamine Substituent.Molecules (Basel, Switzerland) · 2026Article
- Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting.Scientific reports · 2025Article
- Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes.Microbiology spectrum · 2025Observational
- Article
- Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.Indian journal of microbiology · 2025Article
- Endoscopic Endonasal Resection of Clival Chordomas.Advances and technical standards in neurosurgery · 2025Review
- Synergy between immune system and antibiotics drives infection control in mice.Frontiers in immunology · 2025Article
- Article
- The long-term impact of an antimicrobial stewardship program in febrile neutropenia: an 8 years follow up.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Marine Antimicrobial Peptide Epinecidin-1 Inhibits Proliferation Induced by Lipoteichoic acid and Causes cell Death in non-small cell lung cancer Cells via Mitochondria Damage.Probiotics and antimicrobial proteins · 2024Article
- Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Why do patients with cancer die?Nature reviews. Cancer · 2024Review
- Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy.Genes and immunity · 2024Article
- Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting.JCO global oncology · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in the treatment and supportive care of patients with malignant disorders, neutropenia remains the major side effect of most antineoplastic regimens. Infections occur frequently in neutropenic patients and are associated with considerable morbidity and mortality. The spectrum of infection continues to change, and is influenced by various factors including local epidemiology, the use of chemoprophylaxis, and the use of central venous catheters and other medical devices. Bacterial infections are common in the early stages of neutropenia, with fungal infections emerging if neutropenia persists beyond 7-10 days. Gram-positive organisms cause most bacteremic infections (although this trend appears to be changing), whereas infections at other sites are often caused by Gram-negative bacilli or are polymicrobial, especially if deep tissue infection is present. Candida spp., and Aspergillus spp., remain the most common fungal pathogens, although several opportunistic fungi have emerged. Resistance to antimicrobial and antifungal agents commonly used for the prevention and treatment of infections in neutropenic patients has become a significant problem. The prompt administration of appropriate, empiric, antimicrobial therapy, prior to the availability of microbiological culture results, is the standard of care. Up to date knowledge of the spectrum of infection and local susceptibility/resistance patterns, is critical. In this report, we describe the current spectrum of infection in patients with malignancies and neutropenia, and emphasize the fact that local and geographic differences are not infrequent. We recommend that individual institutions conduct periodic epidemiological surveys in order to have the latest data available for the optimal management of their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.